GENFIT Unveils Clinical Insights on Nangibotide for ACLF

GENFIT has announced encouraging clinical data for nangibotide, its promising candidate for acute-on-chronic liver failure (ACLF), with Phase 2 results anticipated by 2027. During The Liver Meeting® in Denver, experts reviewed nangibotide's potential, highlighting its proven safety and efficacy in prior studies, including trials related to septic shock and COVID-19.

Nangibotide targets the TREM-1 pathway, aimed at mitigating excessive inflammation without compromising immune response. This approach is crucial for ACLF treatment, where systemic inflammation often leads to organ failure.

The upcoming UPWARD Phase 2a trial will assess nangibotide in ACLF patients with bacterial infections. It will focus on safety and pharmacokinetics, with initial findings expected in late 2027.